BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
BioNxt Solutions (OTCQB:BNXTF) has reported significant progress on its targeted chemotherapy delivery platform, first announced in July 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioNxt Solutions (OTCQB:BNXTF) has reported significant progress on its targeted chemotherapy delivery platform, first announced in July 2025. The company's novel technology aims to concentrate chemotherapy drugs around tumors while protecting healthy tissue through a dual-action mechanism.
The platform has demonstrated potential for a 10-fold increase in therapeutic effect in vitro while maintaining healthy cell safety. The R&D team has created a molecule databank and identified numerous high-priority targets, with one promising candidate selected for proof of concept based on its pharmacokinetic properties.
The company expects to announce its patent strategy and next R&D steps soon, along with signing a definitive agreement in the coming weeks.
Positive
- Novel drug delivery platform shows 10-fold increase in therapeutic effect in vitro
- Dual-action mechanism potentially reduces systemic toxicity while maintaining efficacy
- Company has identified promising drug candidate for proof of concept
- Pending definitive agreement and patent strategy announcements
Negative
- Technology still in early development stage with only in-vitro data
- No clinical validation yet of the platform's effectiveness
- Timeline for definitive agreement completion remains uncertain
Details
News Market Reaction – BNXTF
The recorded move for BNXTF in the trading session of this news was -3.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, BC, BC / ACCESS Newswire / October 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a development-stage biopharmaceutical company specializing in advanced drug-delivery technologies, is pleased to report a significant advancement regarding its targeted chemotherapy delivery platform and a related definitive transaction update.
First announced July 8, 2025, the novel technology is a potential breakthrough targeted chemotherapy delivery platform designed to address a critical unmet need by localizing toxic chemotherapy drugs inside and around tumours while minimizing systemic exposure. The proprietary targeted drug delivery system employs a novel, dual-action mechanism that first concentrates potent chemotherapy drugs in close proximity to tumours, then rapidly neutralizes free drug molecules outside of the tumour location to protect healthy tissue. This targeted approach has demonstrated in-vitro potential to enable a 10-fold increase in therapeutic effect while maintaining the safety of healthy cells, significantly expanding the therapeutic window.
The research and development team has initiated the creation of a molecule databank to feed prospective candidate molecules into the proprietary computational model to prioritize chemotherapy drugs for advanced research. The team has already identified a short-list of dozens of high-priority targets. From this short-list, the team is now focused on one drug shows particular promise for proof of concept due to its pharmacokinetic properties. The prioritized candidate is currently used in both traditional chemotherapy and in other advanced targeted oncology treatments.
The Company looks forward to announcing the next research and development steps and its patent strategy in the coming weeks and months. In addition, the Company expects to sign a definitive agreement in the coming weeks and will report an update accordingly.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3.
To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.